8-K: IGM Biosciences Receives Nasdaq Non-Compliance Notice for Market Value

IGM Biosciences, Inc. has received a notice from Nasdaq indicating non-compliance with the minimum Market Value of Listed Securities requirement, initiating a 180-day period to regain compliance.

Summary

• IGM Biosciences, Inc. (the "Company") received a written notice from The Nasdaq Stock Market LLC on June 6, 2025.
• The notice indicates that the Company is no longer in compliance with the minimum Market Value of Listed Securities (MVLS) of $50,000,000 required for continued listing on The Nasdaq Global Select Market, as per Nasdaq Listing Rule 5450(b)(2)(A).
• This notice does not immediately affect the listing of the Company's common stock, which continues to trade under the symbol IGMS.
• The Company has a period of 180 calendar days, until December 3, 2025 (the "Compliance Date"), to regain compliance.
• To regain compliance, the Company's MVLS must close at $50,000,000 or more for a minimum of 10 consecutive business days prior to the Compliance Date.
• If compliance is not regained, Nasdaq will notify the Company of delisting, at which point the Company may appeal the determination to a Nasdaq hearings panel.
• The Company intends to actively monitor its MVLS and may consider options to regain compliance, including potentially transferring its listing to The Nasdaq Capital Market.

Sentiment

Score: 3

Explanation: The company received a non-compliance notice from Nasdaq due to its market value falling below the required threshold, which is a negative event. However, it has a 180-day period to regain compliance, and management has stated intentions to monitor and address the issue, including potential transfer to another Nasdaq market, which mitigates immediate severe negative sentiment.

Negatives

• The Company received a non-compliance notice from Nasdaq for failing to meet the minimum Market Value of Listed Securities (MVLS) requirement of $50,000,000.
• There is a risk of delisting from The Nasdaq Global Select Market if compliance is not regained by December 3, 2025.
• There is no assurance that the Company will be able to regain compliance with the MVLS Requirement or maintain compliance with other listing requirements.
• There is no assurance that the Company can satisfy the requirements necessary to transfer its listing to The Nasdaq Capital Market.

Risks

• Failure to regain compliance with Nasdaq Listing Rule 5450(b)(2)(A) (MVLS Requirement) by the Compliance Date of December 3, 2025.
• Potential delisting of the Company's common stock from The Nasdaq Global Select Market.
• Inability to maintain compliance with any other Nasdaq listing requirements.
• Inability to satisfy the requirements necessary to transfer the listing of its Common Stock to The Nasdaq Capital Market.

Future Outlook

The Company intends to actively monitor its Market Value of Listed Securities (MVLS) and may consider implementing available options to regain compliance with the MVLS Requirement. It may also choose to transfer the listing of its Common Stock to The Nasdaq Capital Market. However, there can be no assurance that the Company will be able to regain compliance or maintain other listing requirements, or satisfy the requirements for a transfer.

Management Comments

• "The Company intends to actively monitor its MVLS and may, if appropriate, consider implementing available options to regain compliance with the MVLS Requirement."
• "The Company may also choose to transfer the listing of its Common Stock to The Nasdaq Capital Market."

Industry Context

This notice highlights the ongoing challenges faced by smaller biotechnology companies in maintaining market capitalization, especially in volatile market conditions or during periods without significant clinical milestones. Maintaining a Nasdaq listing is crucial for liquidity, investor visibility, and access to capital markets within the biotechnology sector.

Stakeholder Impact

• Shareholders: Potential risk of delisting could reduce liquidity and investor confidence, potentially impacting share price. Uncertainty regarding the Company's future listing status on a major exchange.

Next Steps

• Actively monitor its Market Value of Listed Securities (MVLS).
• Consider implementing available options to regain compliance with the MVLS Requirement.
• Regain compliance by having its MVLS close at $50,000,000 or more for a minimum of 10 consecutive business days prior to December 3, 2025.
• Potentially choose to transfer the listing of its Common Stock to The Nasdaq Capital Market.
• Appeal a delisting determination to a Nasdaq hearings panel if compliance is not regained.

Key Dates

Recommendation

Keywords

IGM Biosciences, IGMS, Nasdaq, delisting, market value, MVLS, non-compliance, listing requirements, biotechnology, pharmaceutical